A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
about
Targeting the molecular and cellular interactions of the bone marrow niche in immunologic diseaseRegulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical developmentMLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonismPlerixaforChemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targetingEuropean data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature.Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compoundsTumor biology and cancer therapy - an evolving relationship.Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.Front-line treatment in younger patients with multiple myeloma.The role of natalizumab in hematopoietic stem cell mobilization.Peripheral blood stem cell mobilization tactics.Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.Plerixafor: a peripheral blood stem cell mobilizer.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Mobilization of hematopoietic stem cells into the peripheral blood.Novel strategies for blood stem cell mobilization: special focus on plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.Mobilization of hematopoietic stem and leukemia cells.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Advances in stem cell mobilization.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.Targeting Neutrophils to Prevent Malaria-Associated Acute Lung Injury/Acute Respiratory Distress Syndrome in Mice.Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.
P2860
Q26865498-6101A270-97F7-4D88-A0C5-72AADC1DA6C1Q27692619-A2855A42-BF48-4767-B530-9F3685E558D0Q28084276-3DFD5C96-781E-4CA0-BBBF-DE052F876589Q28658170-E655C46E-F7CB-439E-B38C-FF4377377FFAQ33885517-38965CF9-F314-44A0-A8E1-89448D5494ECQ34010429-C9864E45-DDC5-4847-BB08-5EB606ABFE07Q34073741-5D654AB3-26C3-4777-93A8-0C3CC44F258CQ34114055-8FF2E731-6AFC-4776-A5CA-8137C0EF6778Q34246928-BA9DAD7C-CCAB-4750-96FF-5D8E6A742133Q35794312-CF2403D0-DFAF-44D4-8E13-1D5543103F00Q35944653-D274B4DA-727A-4A61-BB30-B01E3F916A9CQ36445393-555D1C9F-3D44-4882-AFC9-C94D01440D73Q36766494-813AC4B2-FE03-4B83-8BEA-5BFDA5C4534FQ36801780-47B9DC0E-1933-43C5-82AA-D457398F9E5FQ37318093-277C05C6-DDF5-4B6C-A897-067539250A08Q37421288-8511492A-5376-4968-A22D-BA40EE07B67AQ37457273-239AE665-848C-492D-9DFB-F19A6EDC1F56Q37536053-079FCF61-2A31-440D-9BE9-C408DFE468CEQ37649251-D7239DDA-94C8-4285-912D-5C454E1A0BE2Q37707195-50D3C9D5-3CDF-4A46-AF09-EA63AC5FC09FQ37735840-60CB04D0-E0A7-4FC3-B1B5-2ED543EB631EQ37772888-7A19CBD2-E3F1-4001-8A3A-F343A75A203FQ37810088-2376A658-A7CE-4B77-A26B-E5F6F5771BC8Q37909447-4826B9CC-7D50-47FB-9036-115086907090Q37921284-CCE23601-108F-4683-BD9E-12A2EE98A4CFQ37923309-25E3EFD2-4C87-4F84-A3F2-5F9EE28DB755Q37949562-749A7CE1-72F5-4A5F-9DAB-47E55A040057Q38077807-131BC6B6-CE08-409E-94C4-F256AB0AC8A9Q38160461-5DA93634-D5E5-46E6-9399-60CAC3BB88E2Q38183225-CFDE7399-FBD8-4737-8D2C-3B26309EA300Q38200909-A4CB9411-B74B-4D8E-BE68-2C5DD351A87EQ38371396-ACF9F8CA-7564-41C8-BC1F-2C447589D5E3Q38880504-D31A659A-78F9-436F-B87C-55A1C1B6A8A1Q38947056-EE38E11B-7E44-411C-8CC1-76B6C610B6F7Q39446714-0D81610C-553F-4DEE-93AE-BA857791C909Q39724267-EA2C8F8D-4D3F-4B38-B130-765626C11D0AQ39958361-74B889D7-0AA8-47D5-A7BC-8EC06CDBFAD8Q40490106-6FF78CD1-0208-4CC2-8D1D-05245E3E602CQ41928814-EFBBDCDC-40C4-449E-B16F-E3A279B6127AQ42173095-38E45FB3-DE7B-475F-992C-23BC599B12BD
P2860
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A phase II study of plerixafor ...... atients with Hodgkin lymphoma.
@en
A phase II study of plerixafor
@nl
type
label
A phase II study of plerixafor ...... atients with Hodgkin lymphoma.
@en
A phase II study of plerixafor
@nl
prefLabel
A phase II study of plerixafor ...... atients with Hodgkin lymphoma.
@en
A phase II study of plerixafor
@nl
P2093
P1476
A phase II study of plerixafor ...... atients with Hodgkin lymphoma.
@en
P2093
Amanda Cashen
Gary Calandra
John DiPersio
Karin Badel
Ron MacFarland
Sandra Lopez
P304
P356
10.1016/J.BBMT.2008.08.011
P50
P577
2008-11-01T00:00:00Z